Molecular pathology of oligodendroglial tumors

Recent Results in Cancer Research

Volumn 171, Issue , 2009, Pages 25-49

  Hartmann, Christian ^a,b   Von Deimling, Andreas ^c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ASTROCYTE; ASTROCYTOMA; CANCER CLASSIFICATION; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CONTROLLED STUDY; GENE; GENOTYPE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MGMT GENE; MOLECULAR BIOLOGY; MOLECULAR MODEL; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; CHROMOSOME ABERRATION; GENETICS; MUTATION; PATHOLOGY; PROGNOSIS;

BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; OLIGODENDROGLIOMA; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 67449100575     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-31206-2_2     Document Type: Review

References (26)

1. Aguirre-Cruz L, Mokhtari K, Hoang-Xuan K, Marie Y, Criniere E, Taillibert S, Lopes M, Delattre JY, Sanson M (2004) Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors. J Neurooncol 67:265-271
2. Alonso ME, Bello MJ, Arjona D, Martinez-Glez V, de Campos JM, Isla A, Kusak E, Vaquero J, Gutierrez M, Sarasa JL, Rey JA (2005) Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas. Am J Clin Pathol 123:900-906 (Pubitemid 40740690)
3. Anguelova E, Beuvon F, Leonard N, Chaverot N, Varlet P, Couraud PO, Daumas-Duport C, Cazaubon S (2005) Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas. Brain Res Mol Brain Res 137:77-88
4. Azzarelli B, Miravalle L, Vidal R (2004) Immunolocalization of the oligodendrocyte transcription factor 1 (Olig1) in brain tumors. J Neuropathol Exp Neurol 63:170-179
5. Bailey P, Bucy P (1929) Oligodendrogliomas of the brain. J Pathol Bacteriol 32:735-754
6. Bailey P, Cushing H (1926) A Classification of Tumors of the Glioma Group on a Histogenetic basis with a Correlation Study of Prognosis. Lippincott, Philadelphia
7. Balls J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008 Dec;116(6):597-602. Epub 2008 Nov 5
8. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP (2008) CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 18:370-377
9. Bello MJ, Leone PE, Nebreda P, de Campos JM, Kusak ME, Vaquero J, Sarasa JL, Garcia-Miguel P, Queizan A, Hernandez-Moneo JL, et al. (1995a) Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 83:160-164
10. Bello MJ, Leone PE, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Pestana A, Rey JA (1995b) Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int J Cancer 64:207-210
11. Bello MJ, Vaquero J, de Campos JM, Kusak ME, Sarasa JL, Saez-Castresana J, Pestana A, Rey JA (1994) Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer 57:172-175
12. Bigner SH, Matthews MR, Rasheed BK, Wiltshire RN, Friedman HS, Friedman AH, Stenzel TT, Dawes DM, McLendon RE, Bigner DD (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375-386
13. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, Schiffer D (2000) CDKN2A/ p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88:554-557
14. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, Luyken C, Sabel M, Zerrouqi A, Wasner M, Van Meir E, Tolnay M, Reifenberger G, Merlo A (2007) Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE 2:e576
15. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 24:4746-4753
16. Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, Feuerstein BG (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842-853
17. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714
18. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C, Jr., et al. (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:2013-2021
19. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479
20. Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61:267-273
21. Chin HW, Hazel JJ, Kim TH, Webster JH (1980) Oligodendrogliomas. I. A clinical study of cerebral oligodendrogliomas. Cancer 45:1458-1466
22. Coleman KE, Brat DJ, Cotsonis GA, Lawson D, Cohen C (2006) Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance. Appl Immunohistochem Mol Morphol 14:109-114
23. Cooke HJ (2004) Silence of the centromeres-not. Trends Biotechnol 22:319-321
24. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK (1997) Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 79:1381-1393
25. Dai C, Lyustikman Y, Shih A, Hu X, Fuller GN, Rosenblum M, Holland EC (2005) The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. Neoplasia 7:397-406
26. Davis FG, Freels S, Grutsch J, Barlas S, Brem S (1998) Survival rates in patients with primary